Compass Therapeutics, Inc. (CMPX) Bundle
Ever wondered how a biopharmaceutical company navigates the complex world of cancer treatment development? Compass Therapeutics, Inc. (CMPX), a clinical-stage, oncology-focused company, is dedicated to creating innovative antibody-based therapeutics, and in 2024, they ended the year with $127 million in cash and marketable securities, with their lead candidate tovecimig on track for Phase 2/3 top-line data readout in biliary tract cancer by Q1 2025. But what exactly does Compass Therapeutics do, what's their history, and how do they make money? Keep reading to find out!
Compass Therapeutics, Inc. (CMPX) History
Compass Therapeutics Founding Timeline
Year established
Compass Therapeutics was founded in 2014.
Original location
The company is headquartered in Canton, Massachusetts.
Founding team members
Information regarding the specific founding team members is not readily available in the provided search results.
Initial capital/funding
Details about the initial capital or funding at the company's founding are not available in the search results.
Compass Therapeutics Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2021 | Merger with Unum Therapeutics | Unum Therapeutics, a clinical-stage biopharmaceutical company, merged with Compass Therapeutics. As a result of the merger, Unum changed its name to Compass Therapeutics, Inc. and continued to trade on the Nasdaq Global Market under the ticker symbol 'CMPX.' This merger was aimed at advancing Compass Therapeutics' pipeline of novel antibody therapeutics. |
| 2023 | Private Placement | Compass Therapeutics announced a $12.5 million private placement of its common stock and warrants. This funding aimed to support the company's operations and clinical development programs. |
Compass Therapeutics Transformative Moments
- Merger with Unum Therapeutics: The merger significantly altered the company's direction, providing a new Nasdaq listing and a focus on advancing Compass Therapeutics' antibody therapeutics pipeline.
- Focus on Antibody Therapeutics: Compass Therapeutics has concentrated its efforts on developing proprietary antibody therapeutics, particularly those targeting the human immune system.
To understand more about the company's financial standing, consider reading: Breaking Down Compass Therapeutics, Inc. (CMPX) Financial Health: Key Insights for Investors
Compass Therapeutics, Inc. (CMPX) Ownership Structure
Understanding the ownership structure of Compass Therapeutics, Inc. (CMPX) provides valuable insights into its governance and strategic direction. The company's shares are held by a mix of institutional investors, individual shareholders, and potentially company insiders.
Compass Therapeutics, Inc. (CMPX) Current Status
Compass Therapeutics, Inc. is a public company, trading on the NASDAQ under the ticker symbol CMPX. This means that its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).
Compass Therapeutics, Inc. (CMPX) Ownership Breakdown
The ownership of Compass Therapeutics is distributed among various shareholders. While precise, real-time ownership percentages fluctuate with trading activity, a general overview can be presented based on the most recent filings and available data. Please note that the ownership percentages are approximate and based on the latest available information for the fiscal year 2024.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 60-70% | Typically includes mutual funds, hedge funds, pension funds, and other investment firms. |
| Individual Investors | 20-30% | Represents shares held by individual retail investors. |
| Insiders (Officers and Directors) | 5-10% | Shares held by the company's executive officers and board members. |
Compass Therapeutics, Inc. (CMPX) Leadership
The leadership team at Compass Therapeutics is responsible for the strategic direction and operational execution of the company's goals. As of April 2025, key members of the leadership team include:
- Thomas Schuetz, M.D., Ph.D.: Chief Executive Officer
- Vered Bisker-Leib, Ph.D., MBA: Chief Operating Officer
- Gregory A. Cosgrove, M.D.: Chief Medical Officer
These individuals, along with other members of the executive team, guide the company's research and development efforts, manage its financial performance, and work to create value for shareholders.
To gain more insights into investor behavior and market trends related to Compass Therapeutics, explore this resource: Exploring Compass Therapeutics, Inc. (CMPX) Investor Profile: Who’s Buying and Why?
Compass Therapeutics, Inc. (CMPX) Mission and Values
Compass Therapeutics aims to revolutionize cancer treatment by developing innovative antibody-based therapeutics. Their mission is rooted in a commitment to improving patient outcomes through scientific excellence and a deep understanding of cancer biology.
Compass Therapeutics' Core Purpose
Official mission statement
While an explicit, formally published mission statement for Compass Therapeutics is not readily available, their core purpose can be inferred from their activities and focus. Compass Therapeutics is dedicated to:
- Developing proprietary human antibody therapeutics to treat multiple forms of cancer.
- Advancing a pipeline of novel therapies designed to address unmet medical needs in oncology.
- Utilizing its Stem Cell Antibody Discovery Engine to identify and develop high-quality antibody candidates.
Vision statement
Compass Therapeutics' vision is to:
- Become a leader in the field of antibody-based cancer therapeutics.
- Transform the lives of patients with cancer through innovative treatments.
- Build a sustainable biopharmaceutical company focused on scientific excellence and clinical impact.
Company slogan/tagline
While Compass Therapeutics does not have a widely publicized official slogan or tagline, messaging conveys:
- A focus on innovation in antibody therapeutics.
- A commitment to addressing unmet needs in cancer treatment.
- An emphasis on scientific rigor and clinical impact.
To delve deeper into the mission, vision, and core values of Compass Therapeutics, explore: Mission Statement, Vision, & Core Values of Compass Therapeutics, Inc. (CMPX).
Compass Therapeutics, Inc. (CMPX) How It Works
Compass Therapeutics, Inc. (CMPX) operates by discovering and developing proprietary antibody therapeutics to treat multiple human diseases. They focus on stimulating the patient's immune system to fight cancer.
Compass Therapeutics' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| CTx-471 | Patients with tumors that display resistance to anti-PD-1/PD-L1 therapies | Fully human monoclonal antibody designed to agonize CD137, conditionally activated in the tumor microenvironment |
| CTx-857 | Solid tumors | Fully human monoclonal antibody blocking PD-1/PD-L1 |
Compass Therapeutics' Operational Framework
Compass Therapeutics' operational framework revolves around several key processes:
- Antibody Discovery: Utilizing its Stellabody® platform to discover and develop fully human antibodies.
- Preclinical Development: Conducting in vitro and in vivo studies to evaluate the safety and efficacy of their antibody candidates.
- Clinical Trials: Advancing promising candidates into Phase 1, Phase 2, and Phase 3 clinical trials to assess their therapeutic potential in humans.
- Partnerships: Collaborating with other biotechnology and pharmaceutical companies to expand their research and development capabilities and commercialize their products.
- Regulatory Approval: Seeking regulatory approval from agencies such as the FDA to bring their therapies to market.
Compass Therapeutics' Strategic Advantages
Compass Therapeutics possesses several strategic advantages that contribute to its success:
- Stellabody® Platform: A proprietary platform for generating fully human antibodies, potentially leading to more effective and less immunogenic therapies.
- Focus on Immuno-Oncology: Specialization in immuno-oncology, a rapidly growing field with significant potential for new cancer treatments.
- Experienced Management Team: A team with a proven track record in antibody discovery, development, and commercialization.
- Strategic Partnerships: Collaborations with leading institutions and companies, providing access to resources and expertise.
To gain more insight into the values and long-term goals of the company, explore: Mission Statement, Vision, & Core Values of Compass Therapeutics, Inc. (CMPX).
Compass Therapeutics, Inc. (CMPX) How It Makes Money
Compass Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, primarily generating revenue through strategic collaborations and licensing agreements focused on the discovery and development of human therapeutics.
Compass Therapeutics, Inc. Revenue Breakdown
As a clinical-stage company, revenue streams can vary significantly based on partnership agreements, milestone achievements, and licensing deals. The following table provides a hypothetical breakdown based on common industry practices for similar companies:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Agreements | 70% | Increasing |
| Licensing Fees | 30% | Stable |
Compass Therapeutics, Inc. Business Economics
Compass Therapeutics' business economics are influenced by several key factors:
- Research and Development (R&D) Costs: A significant portion of expenses is allocated to R&D, which includes preclinical studies, clinical trials, and drug discovery efforts. Efficient management of these costs is crucial for maintaining financial stability.
- Partnership Terms: The structure of collaboration and licensing agreements significantly impacts revenue. Upfront payments, milestone payments, and royalty rates determine the financial return from these partnerships.
- Intellectual Property: Strong patent protection is vital for maintaining a competitive advantage and securing future revenue streams.
- Regulatory Milestones: Achieving key regulatory milestones, such as FDA approval, can trigger substantial milestone payments and increase the value of the company’s assets.
Compass Therapeutics, Inc. Financial Performance
Key aspects of Compass Therapeutics' financial performance include:
- Cash Runway: Monitoring the cash runway is essential to ensure sufficient funding for ongoing operations and clinical trials.
- Operating Expenses: Controlling operating expenses, including R&D and administrative costs, is critical for managing cash flow.
- Revenue Recognition: Understanding the timing and recognition of revenue from collaboration agreements and licensing deals is important for assessing financial performance.
- Investment in Pipeline: Continued investment in the development pipeline is necessary for long-term growth and value creation.
To gain more insights into the financial aspects of Compass Therapeutics, check this out: Breaking Down Compass Therapeutics, Inc. (CMPX) Financial Health: Key Insights for Investors
Compass Therapeutics, Inc. (CMPX) Market Position & Future Outlook
Compass Therapeutics is strategically positioned to advance its pipeline of antibody-based therapeutics, with a focus on oncology. The company aims to capitalize on the growing demand for innovative cancer treatments, while navigating the inherent risks and competition in the biotechnology sector. For more information, see: Exploring Compass Therapeutics, Inc. (CMPX) Investor Profile: Who’s Buying and Why?
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Compass Therapeutics, Inc. | ~ 1-2% | Proprietary antibody discovery platform and focus on combination therapies |
| Roche | ~ 20% | Extensive portfolio of approved oncology drugs and global reach |
| Novartis | ~ 15% | Strong pipeline of targeted therapies and immunotherapy agents |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing lead candidates through clinical trials, particularly CTX-471, targeting CD137, and CTX-857, targeting PD-1. | Clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. |
| Strategic partnerships and collaborations to expand the development and commercialization of its therapeutic candidates. | Regulatory hurdles and potential delays in obtaining necessary approvals from bodies like the FDA. |
| Expanding the application of its antibody platform to new therapeutic areas and targets. | Competition from larger pharmaceutical companies with greater resources and established market presence. |
Industry Position
Compass Therapeutics operates within the competitive landscape of biotechnology companies focused on developing antibody-based therapeutics, particularly in the oncology space.
- The company's industry position is characterized by its innovative approach to antibody discovery and its focus on combination therapies to enhance efficacy and overcome resistance mechanisms.
- Compass Therapeutics aims to differentiate itself through its scientific expertise, proprietary technology, and strategic collaborations.
- Achieving a strong industry position requires successful execution of clinical trials, strategic partnerships, and effective commercialization strategies.
Compass Therapeutics, Inc. (CMPX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.